Continued investment in research and development
First written in FY2017-Q3. 24 of 39 entries say "Advanced", first in FY2017. Latest entry: FY2027-H1.
42 other companies' latest entry also says "Other".
- FY2027-H1Year-on-year decrease in research and development expensesAnnual report
「The Group's total R&D activities during the current interim consolidated fiscal period amounted to ¥1,226 million.」
R&D expenses decreased from ¥1,346 million in the previous interim period to ¥1,226 million. The main component was costs related to obtaining approval for partial changes to the approved particulars for the manufacture and sale of Acurago®. - FY2026AdvancedAnnual report
「At the end of the consolidated fiscal year, the Group had 23 R&D personnel, and total R&D expenses were ¥2,678 million. The main component of the Group's R&D expenses was manufacturing-related costs for the SB623 chronic-phase traumatic brain injury program ahead of obtaining marketing approval.」
R&D expenses increased from ¥2,357 million in the previous fiscal year to ¥2,678 million, with spending recorded for manufacturing-related costs associated with obtaining approval for partial changes to the approved particulars of Acurago®. - FY2026-H1AdvancedAnnual report
「The Group's total R&D activities during the current interim consolidated fiscal period amounted to ¥1,346 million.」
R&D expenses increased from ¥1,024 million in the previous interim period to ¥1,346 million, and spending on R&D activities related to obtaining approval for partial changes to the approved particulars of Acurago® increased. - FY2025Continued decline in research and development expensesAnnual report
「At the end of the consolidated fiscal year, the Group had 20 R&D personnel, and total R&D expenses were ¥2,357 million. The main component of the Group's R&D expenses was manufacturing-related costs for the SB623 chronic-phase traumatic brain injury program ahead of obtaining marketing approval.」
R&D expenses decreased from ¥2,849 million in the previous fiscal year to ¥2,357 million, and R&D personnel totaled 20. The main component was manufacturing-related costs for obtaining marketing approval for Acurago®. - FY2025-H1Research and development expenses continued to decline year on yearAnnual report
「The Group's total R&D activities during the current interim consolidated fiscal period amounted to ¥1,024 million.」
R&D expenses decreased from ¥2,112 million in the same interim period of the previous year to ¥1,024 million, but R&D activities related to marketing approval and manufacturing preparations for the SB623 chronic-phase traumatic brain injury program are continuing. - FY2025-Q1Research and development expenses continued to decline year on yearAnnual report
「The Group's total R&D activities during the first quarter of the current consolidated fiscal year amounted to ¥387 million.」
R&D expenses decreased from ¥1,048 million in the same period of the previous year to ¥387 million, but R&D activities, centered on manufacturing-related costs for the SB623 chronic-phase traumatic brain injury program ahead of marketing approval, are continuing. - FY2024Decrease in R&D expenses and R&D personnelAnnual report
「At the end of the consolidated fiscal year, the Group had 20 R&D personnel, and total R&D expenses were ¥2,849 million.」
R&D expenses decreased from ¥6,118 million in the previous fiscal year to ¥2,849 million, and R&D personnel decreased from 41 to 20. The main expenses were manufacturing-related costs for the SB623 chronic-phase traumatic brain injury program ahead of obtaining marketing approval. - FY2024-Q3Year-on-year decrease in research and development expensesAnnual report
「The Group's total R&D activities during the first nine months of the current consolidated fiscal year amounted to ¥2,447 million.」
R&D expenses decreased from ¥4,981 million in the same period of the previous year to ¥2,447 million, but R&D activities, centered on manufacturing-related costs for the SB623 chronic-phase traumatic brain injury program ahead of marketing approval, are continuing. - FY2024-Q2Year-on-year decrease in research and development expensesAnnual report
「The Group's total R&D activities during the first half of the current consolidated fiscal year amounted to ¥2,112 million.」
R&D expenses decreased from ¥3,620 million in the same period of the previous year to ¥2,112 million, but R&D activities, centered on manufacturing-related costs for the SB623 chronic-phase traumatic brain injury program ahead of marketing approval, are continuing. - FY2024-Q1Year-on-year decrease in research and development expensesAnnual report
「The Group's total R&D activities during the first quarter of the current consolidated fiscal year amounted to ¥1,048 million.」
R&D expenses decreased from ¥1,370 million in the same period of the previous year to ¥1,048 million, but R&D activities, centered on manufacturing-related costs for the SB623 chronic-phase traumatic brain injury program ahead of marketing approval, are continuing. - FY2023AdvancedAnnual report
「At the end of the consolidated fiscal year, the Group had 41 R&D personnel, and total R&D expenses were ¥6,118 million. The main component of the Group's R&D expenses was manufacturing-related costs for the SB623 chronic-phase traumatic brain injury program ahead of obtaining marketing approval.」
R&D expenses increased from ¥4,955 million in the previous fiscal year to ¥6,118 million, and investment in manufacturing-related costs ahead of obtaining marketing approval expanded. - FY2023-Q3AdvancedAnnual report
「The Group's total R&D activities during the first nine months of the current consolidated fiscal year amounted to ¥4,981 million.」
R&D expenses increased from ¥3,546 million in the same period of the previous year to ¥4,981 million, and R&D investment, including manufacturing-related costs ahead of obtaining marketing approval, is expanding. - FY2023-Q2AdvancedAnnual report
「The Group's total R&D activities during the first half of the current consolidated fiscal year amounted to ¥3,620 million.」
R&D expenses increased from ¥2,251 million in the same period of the previous year to ¥3,620 million, and R&D investment, including manufacturing-related costs for the SB623 chronic-phase traumatic brain injury program ahead of obtaining marketing approval, is expanding. - FY2023-Q1AdvancedAnnual report
「The Group's total R&D activities during the first quarter of the current consolidated fiscal year amounted to ¥1,370 million.」
R&D expenses increased from ¥1,126 million in the same period of the previous year to ¥1,370 million, and R&D investment, including manufacturing-related costs for the SB623 chronic-phase traumatic brain injury program ahead of its marketing approval application, is expanding. - FY2022AdvancedAnnual report
「At the end of the consolidated fiscal year, the Group had 61 R&D personnel, and total R&D expenses were ¥4,955 million.」
R&D personnel increased from 57 in the previous fiscal year to 61, and R&D expenses increased from ¥4,071 million to ¥4,955 million. The main expenses were manufacturing-related costs for the SB623 chronic-phase traumatic brain injury program ahead of its marketing approval application. - FY2022-Q3AdvancedAnnual report
「The Group's total R&D activities during the first nine months of the current consolidated fiscal year amounted to ¥3,546 million.」
R&D expenses increased from ¥2,974 million in the same period of the previous year to ¥3,546 million, and R&D investment, including manufacturing-related costs for the SB623 chronic-phase traumatic brain injury program ahead of its marketing approval application, is expanding. - FY2022-Q2AdvancedAnnual report
「The Group's total R&D activities during the first half of the current consolidated fiscal year amounted to ¥2,251 million.」
R&D expenses increased from ¥1,798 million in the same period of the previous year to ¥2,251 million, and R&D investment, including manufacturing-related costs for the SB623 chronic-phase traumatic brain injury program ahead of its marketing approval application, is expanding. - FY2022-Q1AdvancedAnnual report
「The Group's total R&D activities during the first quarter of the current consolidated fiscal year amounted to ¥1,126 million.」
R&D expenses increased from ¥857 million in the same period of the previous year to ¥1,126 million. Investment in R&D activities, centered on manufacturing-related costs for the SB623 chronic-phase traumatic brain injury program ahead of its marketing approval application, is expanding. - FY2021Decline in R&D expensesAnnual report
「At the end of the consolidated fiscal year, the Group had 57 R&D personnel, and total R&D expenses were ¥4,071 million.」
R&D expenses decreased from ¥4,327 million in the previous fiscal year to ¥4,071 million, but R&D activities, centered on manufacturing-related costs for the SB623 chronic-phase traumatic brain injury program ahead of its marketing approval application, are continuing. - FY2021-Q3AdvancedAnnual report
「The Group's total R&D activities during the first nine months of the current consolidated fiscal year amounted to ¥2,974 million.」
R&D expenses increased from ¥2,862 million in the same period of the previous year to ¥2,974 million, and R&D activities, including manufacturing-related costs for the chronic-phase traumatic brain injury program ahead of its marketing approval application, continue to expand. - FY2021-Q2Year-on-year decrease in research and development expensesAnnual report
「The Group's total R&D activities during the first half of the current consolidated fiscal year amounted to ¥1,798 million.」
R&D expenses decreased from ¥2,013 million in the same period of the previous year to ¥1,798 million. Meanwhile, R&D activities, centered on manufacturing-related costs for the chronic-phase traumatic brain injury program ahead of its marketing approval application, are continuing. - FY2021-Q1Decline in R&D expensesAnnual report
「The Group's total R&D activities during the first quarter of the current consolidated fiscal year amounted to ¥857 million.」
R&D expenses decreased from ¥1,095 million in the same period of the previous year to ¥857 million, but R&D activities, including manufacturing-related costs for the SB623 chronic-phase traumatic brain injury program ahead of its marketing approval application, are continuing. - FY2020AdvancedAnnual report
「At the end of the consolidated fiscal year, the Group had 55 R&D personnel, and total R&D expenses were ¥4,327 million.」
R&D expenses increased from ¥3,721 million in the previous year to ¥4,327 million, and R&D personnel increased to 55. - FY2020-Q3AdvancedAnnual report
「The Group's total R&D activities during the first nine months of the current consolidated fiscal year amounted to ¥2,862 million.」
R&D expenses increased from ¥2,497 million in the same period of the previous year to ¥2,862 million, indicating expanded investment in 2 clinical development programs. - FY2020-Q2AdvancedAnnual report
「The Group's total R&D activities during the first half of the current consolidated fiscal year amounted to ¥2,013 million.」
R&D expenses increased from ¥1,669 million in the same period of the previous year to ¥2,013 million, indicating expanded investment in the clinical development of chronic-phase cerebral infarction and chronic-phase traumatic brain injury. - FY2020-Q1AdvancedAnnual report
「The Group's total R&D activities during the first quarter of the current consolidated fiscal year amounted to ¥1,095 million.」
R&D expenses increased from ¥972 million in the same period of the previous year to ¥1,095 million, and investment in the clinical development of chronic-phase cerebral infarction and chronic-phase traumatic brain injury continues to expand. - FY2019Decline in R&D expensesAnnual report
「At the end of the consolidated fiscal year, the Group had 33 R&D personnel, and total R&D expenses were ¥3,721 million.」
R&D expenses decreased from ¥4,156 million in the previous year to ¥3,721 million, but R&D activities, centered on clinical trials for chronic-phase cerebral infarction and chronic-phase traumatic brain injury, are continuing. - FY2019-Q3Research and development expenses continued to decline year on yearAnnual report
「Research and development activities across the Group amounted to ¥2,497 million during the nine months ended 31 December.」
Research and development expenses decreased from ¥2,999 million in the same period of the previous year to ¥2,497 million, but investment in the two clinical development programs for chronic-stage cerebral infarction and chronic-stage traumatic brain injury continued. - FY2019-Q2Decline in R&D expensesAnnual report
「Research and development activities across the Group amounted to ¥1,669 million during the six months ended 30 September.」
Research and development expenses decreased from ¥2,001 million in the same period of the previous year to ¥1,669 million, but research and development investment in the two clinical development programs continued. - FY2019-Q1AdvancedAnnual report
「Research and development activities across the Group amounted to ¥972 million during the three months ended 30 June.」
Research and development expenses increased from ¥929 million in the same period of the previous year to ¥972 million, indicating continued and increased investment in the two clinical development programs. - FY2018AdvancedAnnual report
「At the end of the fiscal year, the Group had 23 research and development employees, and total research and development expenses amounted to ¥4,156 million.」
Research and development expenses increased from ¥2,058 million in the previous year to ¥4,156 million, indicating increased investment in the two trials for chronic-stage cerebral infarction and chronic-stage traumatic brain injury. - FY2018-Q3AdvancedAnnual report
「Research and development activities across the Group amounted to ¥2,999 million during the nine months ended 31 December.」
Research and development expenses increased from ¥1,416 million in the same period of the previous year to ¥2,999 million, indicating increased investment in research and development. - FY2018-Q2AdvancedAnnual report
「Research and development activities across the Group amounted to ¥2,001 million during the six months ended 30 September.」
Research and development expenses increased from ¥944 million in the same period of the previous year to ¥2,001 million, indicating increased investment in research and development. - FY2018-Q1AdvancedAnnual report
「Research and development activities across the Group amounted to ¥929 million during the three months ended 30 June.」
Research and development expenses amounted to ¥929 million in the first quarter, up from ¥367 million in the same period of the previous year. - FY2017AdvancedAnnual report
「At the end of the fiscal year, the Group had 23 research and development employees, and total research and development expenses amounted to ¥2,058 million.」
Research and development expenses increased to ¥2,058 million from ¥1,695 million in the previous year. The main targets were the Phase II trial for traumatic brain injury and the Phase IIb trial for chronic-stage cerebral infarction. - FY2017-Q3First statedAnnual report
「Research and development activities across the Group amounted to ¥1,416 million during the nine months ended 31 December.」
Research and development expenses amounted to ¥1,416 million during the nine months ended 31 December.